OHI holds its post-earnings gains as options hedging fades

Omega Healthcare Investors has just reported Q3 results and the stock is holding its ground, with shorts trimmed, options defensiveness unwinding, and the analyst debate now focused on how much of the bull case is already in the price.

The clearest post-earnings shift is in options sentiment. The put/call ratio has dropped to 1.26, almost 1.5 standard deviations below its 20-day mean of 1.35. That is a meaningful reversal from the more defensive posture that built through October, when the ratio was running above 1.38. Investors who were paying for downside protection ahead of the print are pulling back. The 52-week range on the PCR runs from 0.34 to 1.80, so the current reading is not extreme in either direction, but the direction of travel is toward less hedging, not more.

The short position is broadly stable but continues to drift lower. Short interest ended the week at 5.09% of the free float, roughly 15 million shares, essentially flat on the week after a small trimming. That follows the pattern documented over the past fortnight: shorts built sharply around October 9, have largely held that level, and are now easing gradually. Borrow costs have fallen 18% over the past week to 0.36%, their lowest level in the 30-day window shown. Availability is exceptionally loose at 2,767%, meaning the lending pool holds far more shares than are currently borrowed. The borrow market is sending no distress signal whatsoever, and the ORTEX short score of 46.5 ranks in the 27th percentile, consistent with a position that is present but not particularly aggressive.

The Street remains cautiously constructive. The consensus sits at Hold with a mean price target of $51.37, roughly 8% above the current price of $47.53. The bulls, led by Citi with a $58 target and Cantor Fitzgerald at $56, point to improving operator coverage ratios, active capital deployment, and a healthcare real estate portfolio that is well-positioned for demographic tailwinds. Citizens added an upgrade to Market Outperform on October 22. The bears counter with SNF reimbursement uncertainty, operator concentration risk, and the lingering question of post-CommuniCare earnings dilution. Barclays maintained its Underweight with a trimmed $48 target, and Wells Fargo cut its Equal-Weight target from $48 to $46 in mid-October. On valuation, the stock trades at a price-to-book of 2.62, up roughly 0.26 points over the past 30 days, and EV/EBITDA has ticked to 14.97. Neither is cheap for a healthcare REIT, which bears on how much upside the consensus target actually implies. Factor scores are genuinely interesting: EPS surprise ranks in the 95th percentile and analyst recommendation momentum ranks in the 92nd, two unusually strong readings. Forward earnings-year-on-year growth, however, scores just 27, suggesting the near-term earnings trajectory is the residual concern.

Peer performance this week adds context. SBRA gained 4.6% and VTR rose 4.4%, both outpacing OHI's 3.0% weekly advance. AHR and HR each moved above 7%. OHI's relative underperformance against some peers is modest, but it marks a slight shift from the prior two weeks when OHI was the standout gainer in the group. The stock is up 4% over the past month and trading near $47.53, within range of Barclays' $48 Underweight target, which frames the debate neatly: at this price, even the bear case offers little technical cushion.

BlackRock filed an updated 13G on October 27 showing its stake at 12.3% of the company, up from 11.3% previously, adding just over 600,000 shares to reach 37.3 million. Cohen & Steers also remains a large presence at 7.85%, having built from 4.64% earlier in the year. Both are passive or quasi-passive holders, so the moves reflect index and fund flows rather than active conviction, but the direction is consistent with the stock maintaining strong institutional support. No activist 13D filings are on the register.

With earnings now behind it, the next scheduled release moves to February 2027. The focus shifts to whether OHI can sustain its recent price gain near the $47 to $48 level where multiple analyst targets converge, and whether the gradual unwinding of October's short build continues or finds a floor.